Eletriptan is a second-generation triptan, approved by FDA for the acute treatment of migraine with or without aura in adults.
Eletriptan is a second-generation triptan, approved by FDA for the acute treatment of migraine with or without aura in adults. It is an orally administered drug with higher lipophilicity and longer duration of action, contributing to its higher efficacy and safety in patients experiencing moderate to severe migraine attacks. It should be only indicated after a clear diagnosis of migraine is established. It is not recommended for treatment of cluster headache and the prophylactic therapy of migraine.1
Pharmacological class: Serotonin (5-HT1B/1D) receptor agonist
Migraine is usually caused due to vasodilation of cranial
vessels and/or release of sensory neuropeptides in the trigeminal system.
Eletriptan acts by blocking 5-HT1B/1D receptors present on sensory nerves and
intracranial blood vessels of trigeminal system, thereby resulting in
constriction of cranial vessels and inhibition of release of neuropeptides.1
Eletriptan is contraindicated in patients with:
The major adverse events associated with the
use of eletriptan are asthenia, nausea, dyspepsia, abdominal pain, chest pain,
dizziness, paresthesia and somnolence1
Several trials has reported the significant clinical efficacy and tolerability of eletriptan in the treatment of acute migraine. Below is a summary of trials indicating efficacy and safety of eletriptan:
Eletriptan
versus placebo
Eletriptan
versus other triptans
Comments (0)